Deutschland (BO87) 뉴스

“Power Up Station” Franchise? Lease?

POWER UP STATION
Become a NIO Power Location Partner
We are looking for location partners to host NIO Power Swap Stations and NIO Power Chargers, NIO's game changing charging solution across the world. If you want to work together to

Morikawa ... Alt: Scheffler

Matsuyama Henley Conners Straka ... 273 .. thank you. GL all.

I’m going to double down ,
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175914843

>>> Trump-backed bill to avert government shutdown passes House despite mutiny threats

The Senate must pass the bill by the end of Friday to avert a shutdown


Fox News

by Elizabeth Elkind , Kelly Phares

March 11, 2025

Belisarian filed annual reports for the last two years of BUSC today:

https://www.otcmarkets.com/financialReportViewer?symbol=BUSC&id=423645

"......there's not a lot to add to Friday's update....."

http://www.pretzelcharts.com/

Just a short update today because I forgot the mainland was going to do their Daylight Wasting Time time change. Hawaii doesn't observe DST, so this change means the market shifts fr

Belisarian filed annual reports for the last two years of BUSC today:

https://www.otcmarkets.com/financialReportViewer?symbol=BUSC&id=423645

Offer them .20 in a block sale. Or is it just a block being held by E-trade name that you see without personal info?
I forgot what the NOBO report looks like.

I had a CEO addicted to that report.
He was pulling it everyday. I think it was SF&IO before he did 6 months i

I agree they are very smart to avoid revocation and to recover from being naked shorted because lots of companies fold. Linda didn't only get in a harvard only on her good looks, like Ham said shes smart as a whip

>>> Trump-backed bill to avert government shutdown passes House despite mutiny threats

The Senate must pass the bill by the end of Friday to avert a shutdown


Fox News

by Elizabeth Elkind , Kelly Phares

March 11, 2025

Interesting posts the last couple of days. It begs the question that if what SDRC is doing is not legitimate, why haven't any complaints been logged? Or as such things not reported once registered?

Ah, very good to know - I'll have to mention that to him. Thank you!

I think we're going to try one by Jet Tila - he supposedly is a great Asian chef. Though I have no idea if I can get some of these ingredients.

https://www.foodnetwork.com/recipes/tom-kha-gai-12346850

JarHead mute about Copper Island geotechnical challenges
and only flashing array numbers on an abandonned mines

Is this willful blindness ?

Don’t rely solely on PRs folks, do serious DD, it’s your money after all

A slope failure on the south wall

StayHumble continues to post the same miss-leading information on a daily basis. The real facts are:

>Kevin Lamb does not work for UBQU, he is a VP at Gentell

>Long term debt has grown fom 1.1M in 2023, to 2.4M in 2024. Overall liabilities jumped from 1.6M to 4.2M

https://x.com/americanmade_ai https://x.com/americanmade_ai/status/1899533367860691232

Department of Education lays off nearly half of workforce


https://thehill.com/homenews/education/5189588-department-of-education-lays-off-nearly-half-of-workforce/?email=a847a43b9c99026a728b4bd541e637625305ce80&emaila=aecd5459be4f02f91b0cd8f3982617fb&emailb=f51ffe75b0642f30b2

He'll DH until Yoshida comes off the IR

Pack
Hbar
Xdc
Link
Xrp
Xlm
Xrp
Algo

Gotta believe that any substantial cash infusion could be a strong catalyst for good things here (share price, offtake agreements, other investment, metal health).

While we patiently await for the Annual report and other news, here is a flashback video where Melvin talked about Veemost and its partnership with Cisco. It's a reminder of why we stay long. It sounds like they had a thriving business prior to going public. The process of reverse merging was a spee

Geron Announces European Commission Approval of RYTELO® (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adults With Transfusion-Dependent Anemia Due to Lower-Risk MDS

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to cha